<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20221107056427N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2022-11-23</date_registration>
      <primary_sponsor>Shahid Beheshti University of Medical Sciences</primary_sponsor>
      <public_title>Determining the effectiveness of erector spinae block under ultrasound guidance in analgesia after lumbar vertebral surgeries</public_title>
      <acronym>ESPB</acronym>
      <scientific_title>Comparison between the analgesic effects of the Erector Spinae Plane Block and direct Infiltration under the Erector Spinae muscles in degenerative lumbar vertebral surgeries</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2022-05-22</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>64</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/66705</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Not used, Assignment: Parallel, Purpose: Supportive, Randomization description: A statistics consultant will perform randomization using permuted block technique. The permuted block technique randomizes patients between groups within a set of study participants, called a block. Treatment assignments within blocks are determined so that they are random in order but that the desired allocation proportions are achieved exactly within each block. The randomization sequences are delivered in sealed opaque envelopes to the anesthesiologist responsible for performing the blocks and induction of anesthesia, Blinding description: Before the start of the study and at the time of patient admission, a full explanation is given in relation to the study, and an optional informed consent form is obtained from the patients to participate in the study. The randomization sequences will be delivered in sealed opaque envelopes to the anesthesiologist responsible for performing the blocks and induction of anesthesia. The principal investigator of the project, the medical personnel, the person in charge of data collection (anesthetist assistant), and the person who analyzes the data are also not aware of the grouping of the study.</study_design>
      <phase>N/A</phase>
      <hc_freetext>Degenerative Lumbar vertebral Surgeries.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group 1:  Degenerative Lumbar vertebral Surgeries using Ultrasound-Guided Erector Spinae Plane Block: Bilateral ultrasound-guided ESPBs were performed with the patient in a prone position after induction of general anesthesia, prior to surgical incision. Blocks will be performed by experienced attending anesthesiologists, all of whom were fellowship-trained in regional anesthesia and were members of a dedicated spine anesthesia service. A C60 curved array ultrasound probe (FUJIFILM SonoSite Edge II Total) with 2-5 MHz was placed in parasagittal orientation in the midline to identify the spinous processes. The probe was translated laterally until the tips of the transverse processes were viewed. A 20-Ga 4-inch Ultraplex needle (B. Braun Medical Inc., PA, USA) was placed in-plane and advanced in a cranial-to-caudal direction until the tip was under the erector spinae plane. Depending on the patient's body mass index (BMI) 20  mL 0.25% rupivacaine was injected bilaterally at the tips of the transverse process/under visual guidance. Intervention 2: Intervention group 2: Degenerative Lumbar vertebral Surgeries using Direct Infiltration Under the Erector Spinae muscles: After the midline incision, the fascia is opened in the midline, then the muscles are dissected subperiosteally, and the muscle dissection continues from the transverse process to its lateral part. After laminectomy and screw insertion, at the end of the surgery, 20 cc of 0.25% rupivacaine solution is injected on each side on the device site.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>No - There is not a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for not sharing IPD is There is no more information</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Parisa Raji</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Imam Hussein Medical, Educational, Research and Medical Center, lower than Martyr Madani Metro, Martyr Madani Ave, Tehran, Iran</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1617763141</zip>
        <telephone>+98 21 7343 0000</telephone>
        <email>Raji1389@gmail.com</email>
        <affiliation>Shahid Beheshti University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Parisa Raji</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Imam Hussein Medical, Educational, Research and Medical Center, lower than Martyr Madani Metro, Martyr Madani Ave, Tehran, Iran</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1617763141</zip>
        <telephone>+98 21 7343 3000</telephone>
        <email>raji1389@gmail.com</email>
        <affiliation>Shahid Beheshti University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Candidate for degenerative lumbar vertebral surgeries with a maximum of 4 screws in one or two adjacent vertebral levels.
ASA class I and II
No history of psychiatric diseases or drug and stimulant abuse
No surgery or fracture in other body parts</inclusion_criteria>
      <agemin>20 years</agemin>
      <agemax>70 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>History of previous lumbar vertebral surgeries
BMI above 30
Duration of surgery more than 4 hours
Bleeding rate more than 20% of body blood volume
Surgery requiring the insertion of more than 4 screws or more than two adjacent lumbar vertebrae</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>S32.0</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Fracture of lumbar vertebra</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Surgery</i_code>
      <i_code>Treatment - Surgery</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group 1:  Degenerative Lumbar vertebral Surgeries using Ultrasound-Guided Erector Spinae Plane Block: Bilateral ultrasound-guided ESPBs were performed with the patient in a prone position after induction of general anesthesia, prior to surgical incision. Blocks will be performed by experienced attending anesthesiologists, all of whom were fellowship-trained in regional anesthesia and were members of a dedicated spine anesthesia service. A C60 curved array ultrasound probe (FUJIFILM SonoSite Edge II Total) with 2-5 MHz was placed in parasagittal orientation in the midline to identify the spinous processes. The probe was translated laterally until the tips of the transverse processes were viewed. A 20-Ga 4-inch Ultraplex needle (B. Braun Medical Inc., PA, USA) was placed in-plane and advanced in a cranial-to-caudal direction until the tip was under the erector spinae plane. Depending on the patient's body mass index (BMI) 20  mL 0.25% rupivacaine was injected bilaterally at the tips of the transverse process/under visual guidance.</i_keyword>
      <i_keyword>Intervention group 2: Degenerative Lumbar vertebral Surgeries using Direct Infiltration Under the Erector Spinae muscles: After the midline incision, the fascia is opened in the midline, then the muscles are dissected subperiosteally, and the muscle dissection continues from the transverse process to its lateral part. After laminectomy and screw insertion, at the end of the surgery, 20 cc of 0.25% rupivacaine solution is injected on each side on the device site.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Postoperative analgesia. Timepoint: 2, 6, 12 and 24 hours after the operation. Method of measurement: Patient file information.</prim_outcome>
      <prim_outcome>Morphine intake. Timepoint: 2, 6, 12 and 24 hours after the operation. Method of measurement: Patient file information.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Fentanyl used during surgery. Timepoint: during the surgery. Method of measurement: observation.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Shahid Beheshti University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2022-05-10</approval_date>
        <contact_name>ethics committee of Shahid Beheshti University of Medical Sciences</contact_name>
        <contact_address>Yemen Street, Shahid Chamran Highway, Tehran Tehran Tehran Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
